Use of obg3 for promoting central nervous system remyelination
The present invention relates to the field of central nervous system (CNS) research. Demyelination of neuronal axons within the CNS underlies the pathogenesis of degenerative diseases of the neuromuscular system, such as multiple sclerosis and hereditary leukodystrophies. Therefore, treatments aimed towards accelerating the repair of myelin sheaths offer a potential therapeutic to ameliorate the symptoms of multiple sclerosis and leukodystrophies. A compound, globular OBG3, has been identified that has immunosuppressive properties. This compound should be effective for accelerating the rate of remyelination and treating multiple sclerosis and leukodystrophies.
1 - 11 . (canceled)
12 . A method of increasing the rate of regeneration of myelin sheaths of axons comprising the step of contacting an oligodendrocyte progenitor cell with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO:6 or a biologically active fragment thereof.
13 . The method according to claim 12 , wherein said method is used to treat multiple sclerosis.
14 . The method according to claim 12 , wherein said method is used to treat hereditary leukodystrophies selected from the group consisting of metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.
15 . The method according to claim 12 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, or 103-244 of SEQ ID NO:6.
16 . The method according to claim 15 , wherein said polypeptide is administered to an individual in need thereof.
17 . The method according to claim 12 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 166-193, amino acids 166-176, or amino acids 167-176 of SEQ ID NO:6 or a biologically active fragment thereof.
18 . The method according to claim 17 , wherein said polypeptide is administered to an individual in need thereof.
19 . The method according to claim 12 , wherein said polypeptide is administered to an individual in need thereof.
20 . A method of increasing the rate of cellular division of oligodendrocyte progenitor cells in which said oligodendrocyte progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO:6 or a biologically active fragment thereof.
21 . The method according to claim 20 , wherein said method is used to treat multiple sclerosis.
22 . The method according to claim 20 , wherein said method is used to treat hereditary leukodystrophies selected from the group consisting of metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.
23 . The method according to claim 20 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, or 103-244 of SEQ ID NO:6.
24 . The method according to claim 23 , wherein said polypeptide is administered to an individual in need thereof.
25 . The method according to claim 20 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 166-193, amino acids 166-176, or amino acids 167-176 of SEQ ID NO:6 or a biologically active fragment thereof.
26 . The method according to claim 25 , wherein said polypeptide is administered to an individual in need thereof.
27 . The method according to claim 20 , wherein said polypeptide is administered to an individual in need thereof.
28 . A method of increasing the rate of migration of oligodendrocyte progenitor cells from the germinal centers to demyelinated axons in the CNS in which said oligodendrocyte progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO:6 or a biologically active fragment thereof.
29 . The method of according to claim 28 , wherein said method is used to treat multiple sclerosis.
30 . The method according to claim 28 , wherein said method is used to treat hereditary leukodystrophies selected from the group consisting of metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.
31 . The method according to claim 28 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, or 103-244 of SEQ ID NO:6.
32 . The method according to claim 31 , wherein said polypeptide is administered to an individual in need thereof.
33 . The method according to claim 31 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 166-193, amino acids 166-176, or amino acids 167-176 of SEQ ID NO:6 or a biologically active fragment thereof.
34 . The method according to claim 33 , wherein said polypeptide is administered to an individual in need thereof.
35 . The method according to claim 31 , wherein said polypeptide is administered to an individual in need thereof.
36 . A method of inducing oligodendrocyte progenitor cells to differentiate into mature dendrocytic cells at sites of demyelination in axons in the CNS in which said oligodendrocyte progenitor cells are contacted with a composition comprising a polypeptide sequence comprising the amino acid sequence of SEQ ID NO:6 or a biologically active fragment thereof.
37 . The method according to claim 36 , wherein said method is used to treat multiple sclerosis.
38 . The method according to claim 36 , wherein said method is used to treat hereditary leukodystrophies selected from the group consisting of metachromatic leukodystrophy, Refsum's disease, adrenoleukodystrophy, Krabbe's disease, phenylketonuria, Canavan disease, Pelizaeus-Merzbacher disease, and Alexander's disease.
39 . The method according to claim 36 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, or 103-244 of SEQ ID NO:6.
40 . The method according to claim 39 , wherein said polypeptide is administered to an individual in need thereof.
41 . The method according to claim 36 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of amino acids 166-193, amino acids 166-176, or amino acids 167-176 of SEQ ID NO:6 or a biologically active fragment thereof.
42 . The method according to claim 41 , wherein said polypeptide is administered to an individual in need thereof.
43 . The method according to claim 36 , wherein said polypeptide is administered to an individual in need thereof.
44 . A method of treating diseases in which demyelination of nerve fibers occurs, comprising the administration of a composition comprising an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, 103-244, 166-193, 166-176, or 167-176 of SEQ ID NO:6 or a biologically active fragment thereof, and a pharmaceutical carrier.
45 . A method for the production of a pharmaceutical composition comprising the addition of a pharmaceutical carrier to an amino acid sequence selected from the group consisting of amino acids 84-244, 85-244, 101 to 244, 102-244, 103-244, 166-193, 166-176, or 167-176 of SEQ ID NO:6 or a biologically active fragment thereof is used as an essential component of the composition.